Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study.

BACKGROUND Aging in men is characterized by a progressive decline in levels of anabolic hormones, such as testosterone, insulinlike growth factor 1 (IGF-1), and dehydroepiandrosterone sulfate (DHEA-S). We hypothesized that in older men a parallel age-associated decline in bioavailable testosterone, IGF-1, and DHEA-S secretion is associated with higher mortality independent of potential confounders. METHODS Testosterone, IGF-1, DHEA-S, and demographic features were evaluated in a representative sample of 410 men 65 years and older enrolled in the Aging in the Chianti Area (InCHIANTI) study. A total of 126 men died during the 6-year follow-up. Thresholds for lowest-quartile definitions were 70 ng/dL (to convert to nanomoles per liter, multiply by 0.0347) for bioavailable testosterone, 63.9 ng/mL (to convert to nanomoles per liter, multiply by 0.131) for total IGF-1, and 50 microg/dL (to convert to micromoles per liter, multiply by 0.027) for DHEA-S. Men were divided into 4 groups: no hormone in the lowest quartile (reference) and 1, 2, and 3 hormones in the lowest quartiles. Kaplan-Meier survival and Cox proportional hazards models adjusted for confounders were used in the analysis. RESULTS Compared with men with levels of all 3 hormones above the lowest quartiles, having 1, 2, and 3 dysregulated hormones was associated with hazard ratios for mortality of 1.47 (95% confidence interval [CI], 0.88-2.44), 1.85 (95% CI, 1.04-3.30), and 2.29 (95% CI, 1.12-4.68), respectively (test for trend, P <.001). In the fully adjusted analysis, only men with 3 anabolic hormone deficiencies had a significant increase in mortality (hazard ratio, 2.44; 95% CI, 1.09-5.46 (test for trend, P <.001). CONCLUSIONS Age-associated decline in anabolic hormone levels is a strong independent predictor of mortality in older men. Having multiple hormonal deficiencies rather than a deficiency in a single anabolic hormone is a robust biomarker of health status in older persons.

[1]  N. Rifai,et al.  Erratum: Androgens and diabetes in men: Results from the Third National Health and Nutrition Examination Survey (NHANES III). (Diabetes Care (2007) 30, (234-238)) , 2007 .

[2]  N. Rifai,et al.  Androgens and Diabetes in Men , 2007, Diabetes Care.

[3]  P. Ponikowski,et al.  Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival , 2006, Circulation.

[4]  S. Bandinelli,et al.  Association Between Hormones and Metabolic Syndrome in Older Italian Men , 2006, Journal of the American Geriatrics Society.

[5]  M. Pfisterer,et al.  Anemia as independent predictor of major events in elderly patients with chronic angina. , 2006, American heart journal.

[6]  Claudio Cobelli,et al.  DHEA in elderly women and DHEA or testosterone in elderly men. , 2006, The New England journal of medicine.

[7]  L. Ferrucci,et al.  DHEAS levels and mortality in disabled older women: the Women's Health and Aging Study I. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[8]  D. Kivlahan,et al.  Low serum testosterone and mortality in male veterans. , 2006, Archives of internal medicine.

[9]  G. Valenti.  Consensus Document on substitution therapy with DHEA in the elderly , 2006, Aging clinical and experimental research.

[10]  S. Bandinelli,et al.  Low testosterone levels and the risk of anemia in older men and women. , 2006, Archives of internal medicine.

[11]  S. Bandinelli,et al.  Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. , 2006, The Journal of clinical endocrinology and metabolism.

[12]  P. Anversa.  Aging and longevity: the IGF-1 enigma. , 2005, Circulation research.

[13]  L. Ferrucci,et al.  The hormonal pathway to frailty in older men. , 2005, Journal of endocrinological investigation.

[14]  S. Bandinelli,et al.  Clinical implications of the reduced activity of the GH-IGF-I axis in older men. , 2005, Journal of endocrinological investigation.

[15]  S. Bandinelli,et al.  Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[16]  S. Leng,et al.  Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty , 2004, Aging clinical and experimental research.

[17]  D. Dunger,et al.  Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  E. Barrett-Connor,et al.  The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. , 2004, The Journal of clinical endocrinology and metabolism.

[19]  R. D'Agostino,et al.  Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. , 2003, The American journal of medicine.

[20]  G. Valenti.  Consensus Document on substitution therapy with testosterone in hypoandrogenic elderly men , 2002, Aging clinical and experimental research.

[21]  D. Ingram,et al.  Biomarkers of Caloric Restriction May Predict Longevity in Humans , 2002, Science.

[22]  R. Wolfe,et al.  Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. , 2002, American journal of physiology. Endocrinology and metabolism.

[23]  K. Khaw,et al.  Dehydroepiandrosterone sulfate and mortality in elderly men and women. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  Luigi Ferrucci,et al.  Subsystems Contributing to the Decline in Ability to Walk: Bridging the Gap Between Epidemiology and Geriatric Practice in the InCHIANTI Study , 2000, Journal of the American Geriatrics Society.

[25]  G. Van den Berghe,et al.  A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.

[26]  A. Vermeulen,et al.  A critical evaluation of simple methods for the estimation of free testosterone in serum. , 1999, The Journal of clinical endocrinology and metabolism.

[27]  The insulin-like growth factor axis and plasma lipid levels in the elderly. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[29]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[30]  P J Garry,et al.  Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. , 1997, Metabolism: clinical and experimental.

[31]  F Berrino,et al.  Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. , 1997, International journal of epidemiology.

[32]  E. Barrett-Connor,et al.  Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. , 1988, Circulation.

[33]  J. Morley,et al.  Endocrinology in aging. , 1988, Disease-a-month : DM.

[34]  E. Barrett-Connor,et al.  A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. , 1986, The New England journal of medicine.

[35]  M. Weissman,et al.  Use of a self-report symptom scale to detect depression in a community sample. , 1980, The American journal of psychiatry.

[36]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.